Sanjay Kaul, a frequent FDA advisor, pointed out the paradox of the large commercial success of the diabetes drugs despite the absence of any proven clinical benefit: "So, we have a drug that yields modest glycemic efficacy, is neutral with respect to cardiometabolic factors (lipids, weight, blood pressure), does not kill you or land you in a hospital, and yet is a blockbuster drug nearly 5 times over
Notices have been issued to those found breaking the rules. Businesses that violate regulations will face license cancellation, fines, and legal action
As mentioned, if not treated otherwise, duodenocutaneous fistulas exhibited poor healing (Tables 1-5 , Fig
Its once-weekly profile and strong clinical data are major reasons it has become so widely discussed in metabolic medicine
One could probably turn the tables and and